Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 60 | 60 |
| 1995 | 1 | 48 | 49 |
| 1996 | 0 | 46 | 46 |
| 1997 | 0 | 53 | 53 |
| 1998 | 0 | 66 | 66 |
| 1999 | 0 | 90 | 90 |
| 2000 | 0 | 98 | 98 |
| 2001 | 0 | 94 | 94 |
| 2002 | 0 | 126 | 126 |
| 2003 | 0 | 157 | 157 |
| 2004 | 0 | 150 | 150 |
| 2005 | 1 | 154 | 155 |
| 2006 | 1 | 121 | 122 |
| 2007 | 3 | 135 | 138 |
| 2008 | 0 | 137 | 137 |
| 2009 | 1 | 126 | 127 |
| 2010 | 2 | 121 | 123 |
| 2011 | 2 | 111 | 113 |
| 2012 | 0 | 94 | 94 |
| 2013 | 3 | 100 | 103 |
| 2014 | 1 | 121 | 122 |
| 2015 | 3 | 103 | 106 |
| 2016 | 0 | 78 | 78 |
| 2017 | 0 | 93 | 93 |
| 2018 | 3 | 83 | 86 |
| 2019 | 1 | 67 | 68 |
| 2020 | 1 | 59 | 60 |
| 2021 | 2 | 58 | 60 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 6 | 6 |
| 2024 | 3 | 24 | 27 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Short-term Outcomes in Infants after General Anesthesia with Low-dose Sevoflurane/Dexmedetomidine/Remifentanil versus Standard-dose Sevoflurane (the TREX Trial). Anesthesiology. 2024 Dec 01; 141(6):1075-1085.
-
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov; 19(6):879-892.
-
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II?trial. Future Oncol. 2024; 20(38):3065-3075.
-
ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications. Biometrics. 2024 Oct 03; 80(4).
-
Novel benzothiazole/benzothiazole thiazolidine-2,4-dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies. Arch Pharm (Weinheim). 2024 Dec; 357(12):e2400504.
-
Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues. Eur J Med Chem. 2024 Dec 05; 279:116904.
-
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024 Dec; 94(6):787-798.
-
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024 Sep 19; 391(11):1002-1014.
-
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. J Clin Oncol. 2024 Oct 10; 42(29):3443-3452.
-
Adverse effects associated with antipsychotic use in older adults. Expert Opin Drug Saf. 2024 Sep; 23(9):1157-1171.